Back to Search
SIMON TOPALIAN, M.D.
M.D.
Cardiovascular Disease Physician
NPI: 1225084353IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
25MA07627900(NJ)
CMS Specialties
PrimaryCARDIOVASCULAR DISEASE (CARDIOLOGY)
Education
OTHER
Class of 1998
Research & Publications (20)
Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
PMID 19581576·Proc Natl Acad Sci U S A·2009
8-other
Nonsynonymous somatic mitochondrial mutations occur in the majority of cutaneous melanomas.
PMID 18477896·Melanoma Res·2008
8-other
Natriuretic peptides: biomarkers not predictive in the intensive care unit.
PMID 17413786·Crit Care Med·2007
8-other
Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor.
PMID 17334368·Nat Immunol·2007
8-other
Cancer regression in patients after transfer of genetically engineered lymphocytes.
PMID 16946036·Science·2006
3-trial
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
PMID 16710025·J Clin Oncol·2006
8-other
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
PMID 16638862·Clin Cancer Res·2006
3-trial
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
PMID 16283570·Ann Surg Oncol·2005
3-trial
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
PMID 16237114·J Immunol·2005
8-other
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
PMID 16087944·J Clin Oncol·2005
3-trial
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
PMID 15800326·J Clin Oncol·2005
3-trial
Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.
PMID 15053864·Hum Gene Ther·2004
8-other
CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation.
PMID 14996715·Cancer Res·2004
8-other
Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR.
PMID 14740490·Biotechniques·2004
4-observational
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
PMID 12915604·J Clin Oncol·2003
3-trial
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
PMID 12912944·Clin Cancer Res·2003
3-trial
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
PMID 12890841·N Engl J Med·2003
3-trial
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
PMID 12826605·Proc Natl Acad Sci U S A·2003
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1 COOPER PLZ
CAMDEN, NJ 08103 - Phone
- (856) 342-2000
Quick Facts
- NPI
- 1225084353
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile